skip to main content
Idioma:
Refinado por: Base de dados/Biblioteca: IngentaConnect Journals remover Nome da Publicação: Journal Of Clinical Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Prognostic factors and clinical outcomes in patients with upper tract urothelial carcinoma undergoing surgery: The Cleveland Clinic experience
Prognostic factors and clinical outcomes in patients with upper tract urothelial carcinoma undergoing surgery: The Cleveland Clinic experience
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prognostic factors and clinical outcomes in patients with upper tract urothelial carcinoma undergoing surgery: The Cleveland Clinic experience

Ahmed, Ramsha ; Sheu, Michael ; Wei, Wei ; Ornstein, Moshe Chaim ; Gilligan, Timothy D. ; Dima, Danai ; Campbell, Steven ; Lee, Byron H ; Weight, Christopher ; Wee, Christopher Eing ; Mian, Omar Y. ; Kaouk, Jihad ; Haber, Georges-Pascal ; Gupta, Shilpa

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4593-4593 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
2
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)

Atkins, Michael B ; Jegede, Opeyemi A ; Haas, Naomi B ; McDermott, David F ; Bilen, Mehmet A ; Stein, Mark ; Sosman, Jeffrey A ; Alter, Robert ; Plimack, Elizabeth R ; Ornstein, Moshe ; Hurwitz, Michael ; Peace, David J ; Signoretti, Sabina ; Denize, Thomas ; Cimadamore, Alessia ; Wu, Catherine J ; Braun, David ; Einstein, David ; Catalano, Paul J ; Hammers, Hans

Journal of clinical oncology, 2022-09, Vol.40 (25), p.2913-2923 [Periódico revisado por pares]

United States: Wolters Kluwer Health

Texto completo disponível

Citações Citado por
3
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B)
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B)

Atkins, Michael B. ; Jegede, Opeyemi ; Haas, Naomi B. ; McDermott, David F. ; Bilen, Mehmet Asim ; Hawley, Jessica ; Sosman, Jeffrey A. ; Alter, Robert S. ; Plimack, Elizabeth R. ; Ornstein, Moshe Chaim ; Hurwitz, Michael E. ; Peace, David J. ; Signoretti, Sabina ; Wu, Catherine J. ; Catalano, Paul J. ; Hammers, Hans J.

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4510-4510 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report

Atkins, Michael B. ; Jegede, Opeyemi ; Haas, Naomi B. ; McDermott, David F. ; Bilen, Mehmet Asim ; Stein, Mark N. ; Sosman, Jeffrey Alan ; Alter, Robert S. ; Plimack, Elizabeth R. ; Ornstein, Moshe Chaim ; Hurwitz, Michael E. ; Peace, David J. ; Signoretti, Sabina ; Denize, Thomas ; Cimadamore, Alessia ; Braun, David A. ; Wu, Catherine J. ; Einstein, David Johnson ; Catalano, Paul J. ; Hammers, Hans J.

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.288-288 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A)
Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A)

Atkins, Michael B. ; Jegede, Opeyemi ; McDermott, David F. ; Haas, Naomi B. ; Bilen, Mehmet Asim ; Stein, Mark N. ; Sosman, Jeffrey A. ; Plimack, Elizabeth R. ; Alter, Robert S. ; Ornstein, Moshe Chaim ; Hurwitz, Michael E. ; Peace, David J. ; Einstein, David Johnson ; Catalano, Paul J. ; Hammers, Hans J. ; Regan, Meredith M.

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.604-604 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)
Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)

Beckermann, Katy ; Campbell, Matthew T ; Haas, Naomi B. ; Ornstein, Moshe Chaim ; Gao, Xin ; Mao, Shifeng S. ; Hammers, Hans J. ; George, Saby ; Nelson, Ariel Ann ; Gourdin, Theodore Stewart ; Keshava-Prasad, Holavanahalli ; Hussain, Arif ; Hoimes, Christopher J. ; Yan, Hongxia ; Esquibel, Vanessa ; McIntyre, Gail ; Geller, Robert B. ; Voss, Martin H ; Rini, Brian I. ; Shah, Neil J.

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4534-4534 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140)
A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140)
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140)

Beckermann, Katy ; Shah, Neil J. ; Vogelzang, Nicholas J. ; Mao, Shifeng S. ; Ornstein, Moshe Chaim ; Hammers, Hans J. ; Gao, Xin ; McDermott, David F. ; Haas, Naomi B. ; Yan, Hongxia ; Esquibel, Vanessa ; Rangwala, Reshma A. ; Campbell, Matthew T

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4599-TPS4599 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC)
Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC)

Chen, Yu-Wei ; Beckermann, Katy ; Haake, Scott Mattox ; Reddy, Anupama ; Shyr, Yu ; Atkins, Michael B. ; Mar, Nataliya ; Ornstein, Moshe Chaim ; Pal, Sumanta Monty ; Zhang, Tian ; Rathmell, Wendy Kimryn ; Rini, Brian I.

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS742-TPS742 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
Impact of primary tumor location, histology, and host factors on objective response to immune checkpoint inhibitors in metastatic urothelial carcinoma
Impact of primary tumor location, histology, and host factors on objective response to immune checkpoint inhibitors in metastatic urothelial carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Impact of primary tumor location, histology, and host factors on objective response to immune checkpoint inhibitors in metastatic urothelial carcinoma

Dawsey, Scott ; Khan, Mohammad Siddique ; Radakovich, Nathan ; Wei, Wei ; Mian, Omar Y. ; Ornstein, Moshe Chaim ; Gilligan, Timothy D. ; Gupta, Shilpa

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.493-493 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
10
Adherence to standard of care (SOC) therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC): A single-institution analysis
Adherence to standard of care (SOC) therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC): A single-institution analysis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Adherence to standard of care (SOC) therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC): A single-institution analysis

Dhillon, Puneet ; Ornstein, Moshe Chaim ; Gupta, Shilpa ; Nizam, Amanda ; Gilligan, Timothy D. ; Martin, Allison ; Bonham, Amanda ; Maroli, Kimberly ; Wee, Christopher Eing

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.103-103 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.